Cargando…

A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China

Limited follow-up data is available on the recovery of Omicron COVID-19 patients after acute illness. It is also critical to understand persistence of neutralizing antibody (NAb) and of T-cell mediated immunity and the role of hybrid immunity in preventing SARS-CoV-2 reinfection. This prospective co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Mengna, Cao, Kangli, Xu, Feixiang, Wu, Xueling, Shen, Yao, Lu, Su, Kuang, Zhongshu, Ding, Hailin, Yuan, Shuyun, Shao, Mian, Gu, Guorong, Xing, Lingyu, Gu, Tianwen, Chen, Shaodie, Sun, Jian, Zhu, Jiamin, Zhang, Xiaoyan, Yang, Yilin, Zhao, Guoping, Huang, Lihong, Xu, Jianqing, Song, Zhenju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563605/ https://www.ncbi.nlm.nih.gov/pubmed/37732336 http://dx.doi.org/10.1080/22221751.2023.2261559

Ejemplares similares

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
por: Kim, Young-Il, et al.
Publicado: (2021)

SARS-CoV-2 reinfection and COVID-19 severity
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
por: Brustolin, Marco, et al.
Publicado: (2021)

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants
por: de La Vega, Marc-Antoine, et al.
Publicado: (2023)

Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave
por: Lu, Guanzhu, et al.
Publicado: (2022)

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
por: Wu, Qianhui, et al.
Publicado: (2023)

Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain)
por: Ciuffreda, Laura, et al.
Publicado: (2023)

Understanding the viral shedding time of Omicron variant BA.2 infection in Shanghai: A population-based observational study
por: Lu, Zhenzhen, et al.
Publicado: (2023)

Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022
por: Chen, Xinhua, et al.
Publicado: (2022)

A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China
por: Cai, Jianpeng, et al.
Publicado: (2023)

Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant
por: Shete, Anita M., et al.
Publicado: (2022)

SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: A case report
por: Hasan, Dlshad Abdullah, et al.
Publicado: (2022)

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants
por: Wang, Bolun, et al.
Publicado: (2022)

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants
por: Fan, Feng, et al.
Publicado: (2023)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

Impaired potency of neutralizing antibodies against cell–cell fusion mediated by SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

RT-LAMP assay for rapid detection of the R203M mutation in SARS-CoV-2 Delta variant
por: Yang, Jianing, et al.
Publicado: (2022)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
por: Wang, Xuan-Yi, et al.
Publicado: (2022)

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022)

Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
por: Xu, Hongqin, et al.
Publicado: (2023)

B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses
por: Lin, Ke, et al.
Publicado: (2022)

Recurrent Tuberculosis and Exogenous Reinfection, Shanghai, China
por: Shen, Guomiao, et al.
Publicado: (2006)

Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2
por: Luo, Mengxiao, et al.
Publicado: (2023)

Tracking trends in COVID-19 vaccines based on 47 different vaccines: A bibliometric review
por: Tao, Zhongbin, et al.
Publicado: (2023)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
por: Zhang, Ting, et al.
Publicado: (2023)

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022)

Coronavirus RNA-dependent RNA polymerase interacts with the p50 regulatory subunit of host DNA polymerase delta and plays a synergistic role with RNA helicase in the induction of DNA damage response and cell cycle arrest in the S phase
por: Quan, Li, et al.
Publicado: (2023)

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
por: Xu, Ke, et al.
Publicado: (2023)

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
por: Xu, Fang, et al.
Publicado: (2022)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort
por: Ma, Ensi, et al.
Publicado: (2022)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Concerns related to the interactions between COVID-19 vaccination and cancer/cancer treatment were barriers to complete primary vaccination series among Chinese cancer patients: A multicentre cross-sectional survey
por: Zhang, Lei, et al.
Publicado: (2023)

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
por: Wei, Dong, et al.
Publicado: (2022)

Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation
por: Bei, Zhu-Chun, et al.
Publicado: (2023)

A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity
por: Li, Yang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_54qt8tpjj8blasjmmlt3s8brhv